Scarica l'app Stockscreener
58.39
0.78%
0.45
Dopo l'orario di chiusura:
58.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$57.94
Aprire:
$58.11
Volume 24 ore:
1.98M
Relative Volume:
0.85
Capitalizzazione di mercato:
$14.47B
Reddito:
$2.38B
Utile/perdita netta:
$833.42M
Rapporto P/E:
19.35
EPS:
3.0172
Flusso di cassa netto:
$917.69M
1 W Prestazione:
+0.40%
1M Prestazione:
-0.24%
6M Prestazione:
+33.07%
1 anno Prestazione:
+41.21%
Intervallo 1D:
$57.94
$58.97
Intervallo di 1 settimana:
$57.51
$61.14
Portata 52W:
$33.76
$61.14
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
58.39 | 14.41B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
(EXEL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exelixis, Inc. (EXEL) stock price, news, quote and history - uk.finance.yahoo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - FXEmpire
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance Australia
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension - webull.com
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - Yahoo Finance
Exelixis (EXEL) Gains Ground: Shares Rise 1.63% to $58.15 as Buyers Hold Mid-Range SupportSize Factor - siam.in
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Exelixis (EXEL) Slips 0.22% to $58.36, Key Support and Resistance in FocusRisk Reward Setups - careplusvn.com
Exelixis (EXEL) Institutional Ownership 2026 $EXEL - MarketBeat
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B - Yahoo Finance
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? - finance.yahoo.com
Exelixis Inc (EX9.MU) Stock Price, News, Quote & History - Yahoo Finance
Exelixis Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle - Yahoo Finance
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) - Seeking Alpha
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Potential Amidst a Competitive Biotech Landscape - DirectorsTalk Interviews
Analysts Offer Insights on NA Companies: Exelixis (EXEL) and HEICO (HEI) - The Globe and Mail
Exelixis FDA Delay Moves Zanzalintinib Decision to March 2027 - TechStock²
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value - webull.com
Form 8K Exelixis Inc For: 11 September By Investing.com - Investing.com Australia
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term - Stocktwits
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug - Investor's Business Daily
FDA extends review of Exelixis drug application for metastatic colorectal cancer - Investing.com Nigeria
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
EXEL Looks 21.5% Overvalued on GF Value™ as PDUFA Delay Sparks Volatility - GuruFocus
FDA extends review of Exelixis’ colorectal cancer drug candidate - endpoints.news
US FDA extends review of Exelixis’ cancer drug - WSAU
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 - AllSci
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months - Yahoo Finance
US FDA extends review of Exelixis' cancer drug - Reuters
Why is Exelixis stock sliding today? By Investing.com - Investing.com Canada
Exelixis stock falls as FDA extends zanzalintinib review By Investing.com - Investing.com South Africa
Exelixis stock falls as FDA extends zanzalintinib review - investing.com
EXEL Looks 24.3% Overvalued on GF Value™ - GuruFocus
Form 8K Exelixis Inc For: 11 September - Investing.com India
FDA Extends Review Timeline for Exelixis Cancer Drug - TipRanks
U.S. FDA extends review of Exelixis' cancer drug - Yahoo Finance
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules - Yahoo Finance
La FDA américaine prolonge l'examen du médicament anticancéreux d'Exelixis - TradingView
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):